This study tested a new vaccine called IVX-A12 that targets two respiratory viruses: RSV and hMPV. It involved 264 healthy adults aged 60 to 85. The goal was to see if the vaccine is safe and triggers a strong immune response compared to a placebo.
Phase: PHASE2 • Sponsor: Icosavax, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated May 05, 2026 11:53 UTC